Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
Oncoimmunology|April 11, 2024
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinomaXue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung AdenocarcinomaZhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Biomarker Research|July 23, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective studyChang Lu, Chong-Rui Xu, Yi-Chen Zhang, et al.
Cell Reports. Medicine|January 19, 2023
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world studyHan-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.
Journal of Extracellular Vesicles|October 4, 2019
Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodulesJia-Tao Zhang, Hao Qin, Fiona Ka Man Cheung, et al.
Clinical Lung Cancer|October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable TargetsHai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
The Lancet. Oncology|December 9, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 studyYi-Long Wu, Yu Yao, Jin-Ji Yang, et al.
Pageof 18